BioCentury | Feb 18, 2021
Finance

CEO, new support announced for $1 billion AMR Action Fund

The AMR Action Fund named Henry Skinner CEO and announced $140 million in support from philanthropies and the European Commission to supplement the $1 billion previously pledged by 23 biopharmaceutical companies.  The fund, announced in...
BioCentury | Feb 12, 2021
Product Development

How COVID-19 drug developers can stay ahead of viral variants

With a combination of genomic surveillance and in vitro laboratory assays, COVID-19 drug developers have the tools to get an early read on the vulnerability of their candidates to viral variants and course...
BioCentury | Feb 12, 2021
Emerging Company Profile

Quell: tweaking Tregs for persistence, potency and stability

London-based Quell is among a new generation of companies springboarding off advances in CAR T cells and gene editing to develop more targeted Treg cell therapies with enhanced persistence, potency and stability.  On Thursday, Quell Therapeutics Ltd.’s...
BioCentury | Feb 10, 2021
Deals

CRISPR play Caribou broadens therapeutics reach with AbbVie deal to develop allogeneic CAR Ts

After giving up rights to CRISPR-Cas9 for most therapeutic applications years ago, Jennifer Doudna-founded Caribou is now teaming up with AbbVie to use a different CRISPR enzyme to create allogeneic CAR...
BioCentury | Feb 9, 2021
Translation in Brief

A sickle cell disease gene therapy; plus a dengue virus inhibitor, a small molecule to enhance memory in Alzheimer’s and a cytokine that mediates synaptic function

A team led by Matthew Porteus at Stanford University corrected the HBB gene in hematopoietic stem cells ex vivo and showed that, after autologous transplantation in a Townes mouse model of sickle cell disease, the...
BioCentury | Feb 6, 2021
Product Development

Picking vaccine strategies that could hold up to COVID variants

As new mutations to SARS-CoV-2 emerge faster than many countries can vaccinate their populations,  pressure is mounting on vaccine developers to pre-empt the variants before they take hold, let alone are properly characterized. And while...
BioCentury | Feb 6, 2021
Deals

Feb. 5 Quick Takes: Veracyte taking out Decipher in cancer dx merger; plus V-Bio, Branson-and-Me, Elucidata, Osel

Veracyte Inc. (NASDAQ:VCYT) is acquiring fellow cancer diagnostics company Decipher Biosciences Inc. for $600 million in a cash-and-stock deal. Tina Nova, Decipher’s president and CEO, will join Veracyte as general manager, urologic cancers.  First close, second fundV-Bio...
BioCentury | Feb 6, 2021
Politics, Policy & Law

Biotech isn’t tech; M&A isn’t all the same

Rep. Katie Porter (D-Calif.) released a report last week that crystallized two urgent tasks for the biopharma industry: to prevent misconceptions about M&A from becoming accepted as facts, and more broadly, to forge a bipartisan...
BioCentury | Feb 4, 2021
Management Tracks

Novo Foundation names Krogsgaard Thomsen CEO; plus Takeda’s Sequeira to become first woman to chair PhRMA and updates from Almirall, Twist, Oncosec and more

Biomedical research foundation Novo Nordisk Foundation named Mads Krogsgaard Thomsen, EVP and CSO at Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) as CEO, effective March 1. He replaces Birgitte Nauntofte, who has been the foundation’s CEO since...
BioCentury | Feb 3, 2021
Management Tracks

Lilly Asia’s Li joins AffaMed as president; plus moves at Actimed, Elicio, Life Biosciences, OncoNano, Tollys, HighTide and Patient Square Capital

China-based in-licensing company AffaMed Therapeutics (Shanghai) Co. Ltd. hired Ji Li as president. Li was most recently a venture partner at Lilly Asia Ventures, and prior to that served as EVP and global head of business development at...
Items per page:
1 - 10 of 3791
BioCentury | Feb 18, 2021
Finance

CEO, new support announced for $1 billion AMR Action Fund

The AMR Action Fund named Henry Skinner CEO and announced $140 million in support from philanthropies and the European Commission to supplement the $1 billion previously pledged by 23 biopharmaceutical companies.  The fund, announced in...
BioCentury | Feb 12, 2021
Product Development

How COVID-19 drug developers can stay ahead of viral variants

With a combination of genomic surveillance and in vitro laboratory assays, COVID-19 drug developers have the tools to get an early read on the vulnerability of their candidates to viral variants and course...
BioCentury | Feb 12, 2021
Emerging Company Profile

Quell: tweaking Tregs for persistence, potency and stability

London-based Quell is among a new generation of companies springboarding off advances in CAR T cells and gene editing to develop more targeted Treg cell therapies with enhanced persistence, potency and stability.  On Thursday, Quell Therapeutics Ltd.’s...
BioCentury | Feb 10, 2021
Deals

CRISPR play Caribou broadens therapeutics reach with AbbVie deal to develop allogeneic CAR Ts

After giving up rights to CRISPR-Cas9 for most therapeutic applications years ago, Jennifer Doudna-founded Caribou is now teaming up with AbbVie to use a different CRISPR enzyme to create allogeneic CAR...
BioCentury | Feb 9, 2021
Translation in Brief

A sickle cell disease gene therapy; plus a dengue virus inhibitor, a small molecule to enhance memory in Alzheimer’s and a cytokine that mediates synaptic function

A team led by Matthew Porteus at Stanford University corrected the HBB gene in hematopoietic stem cells ex vivo and showed that, after autologous transplantation in a Townes mouse model of sickle cell disease, the...
BioCentury | Feb 6, 2021
Product Development

Picking vaccine strategies that could hold up to COVID variants

As new mutations to SARS-CoV-2 emerge faster than many countries can vaccinate their populations,  pressure is mounting on vaccine developers to pre-empt the variants before they take hold, let alone are properly characterized. And while...
BioCentury | Feb 6, 2021
Deals

Feb. 5 Quick Takes: Veracyte taking out Decipher in cancer dx merger; plus V-Bio, Branson-and-Me, Elucidata, Osel

Veracyte Inc. (NASDAQ:VCYT) is acquiring fellow cancer diagnostics company Decipher Biosciences Inc. for $600 million in a cash-and-stock deal. Tina Nova, Decipher’s president and CEO, will join Veracyte as general manager, urologic cancers.  First close, second fundV-Bio...
BioCentury | Feb 6, 2021
Politics, Policy & Law

Biotech isn’t tech; M&A isn’t all the same

Rep. Katie Porter (D-Calif.) released a report last week that crystallized two urgent tasks for the biopharma industry: to prevent misconceptions about M&A from becoming accepted as facts, and more broadly, to forge a bipartisan...
BioCentury | Feb 4, 2021
Management Tracks

Novo Foundation names Krogsgaard Thomsen CEO; plus Takeda’s Sequeira to become first woman to chair PhRMA and updates from Almirall, Twist, Oncosec and more

Biomedical research foundation Novo Nordisk Foundation named Mads Krogsgaard Thomsen, EVP and CSO at Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) as CEO, effective March 1. He replaces Birgitte Nauntofte, who has been the foundation’s CEO since...
BioCentury | Feb 3, 2021
Management Tracks

Lilly Asia’s Li joins AffaMed as president; plus moves at Actimed, Elicio, Life Biosciences, OncoNano, Tollys, HighTide and Patient Square Capital

China-based in-licensing company AffaMed Therapeutics (Shanghai) Co. Ltd. hired Ji Li as president. Li was most recently a venture partner at Lilly Asia Ventures, and prior to that served as EVP and global head of business development at...
Items per page:
1 - 10 of 3791